Anderton MJ, Jukes R, Lamb JH, Manson MM, Gescher AJ, Steward WP, Williams ML (2003)  Liquid chromatography assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. J. Chromatog. 787: 281-291
Brown K, Carmichael PL (2003)  Correspondence re: M Sharma et al., “Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture”. Biochem. Biophys. Res. Commun. 310: 1039
   Brown K, Harvey CA, Turteltaub KW, Shields SJ (2003) Structural characterization of carcinogen-modified oligodeoxynucleotide adducts using matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 38, 68-79
 
Cai H, Verschoyle RD, Steward WP, Gescher AJ (2003) Determination of the flavone tricin in human plasma by high-performance liquid chromatography. Biomed. Chromatog. 17: 435-439
 
Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Hansen JB, Steward WP, Skov T, Burcharth F, Evans TRJ (2003)  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Brit. J. Cancer   89: 252-257
 
   Donald S, Verschoyle, RD, Edwards ER, Judah DJ, Davies R, Riley J, Dinsdale D, Lopez-Lazaro LL, Smith AG, Gant TW, Greaves P, Gescher AJ (2002) Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat.  Cancer Res. 62: 4256-4262
   Donald S, Verschoyle RD, Greaves P, Gant TW, Colombo T, Zaffaroni M, Frapolli R, Zucchetti M, D'Incalci M, Meco D, Riccardi R, Lopez-Lazaro L, Jimeno J, Gescher AJ (2003) Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 63: 5902-5908
   Farmer PB, Bartsch H, Boobis A, Chipman K, Gescher A, Kadlubar FF, Manson MM, Phillips DH, Shuker DEG, Swenberg JA, Tannenbaum SR, Wild CP (2002) Basic or applied, it’s the interaction that counts. Nature 417, 117
     Fillingham, Barsukov IG, Damblon CF, Gescher AJ, Roberts GCK (2003)  Synthesis of a simplified bryostatin C-ring analog that binds to the CRD2 of human PKC-alpha, and construction of a novel BC-analog by an unusual Julia olefination process. Org. Lett. 5: 499-50
Garcea G, Sharma RA, Dennison A, Steward WP, Gescher AJ, Berry DP (2003) Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Europ. J. Cancer 39: 1041-1052
   Gescher AJ, Steward WP (2003) Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol. Biomarkers & Prev. 12 : 953-957
Gescher AJ, Sharma RA, Steward WP (2003) Cancer prevention and delay are as important as cure. Lancet Oncol. 4: 72-73
Howells L, Gallacher-Horley B, Houghton CE, Manson MM, Hudson EA.  Indole-3-carbinol inhibits Akt/PKB and induces apoptosis in the human breast tumor cell line MDA MB-468, but not in the non-tumorigenic HBL-100 line (2002). Molec. Cancer Ther. 1, 1161-1172
Hudson EA, Howells LM, Gallacher-Horley B, Fox LH, Gescher AJ, Manson MM (2003) Growth-inhibitory effects of the chemopreventive agent indole- 3-carbinol are increased in combination with the polyamine putrescine in the SW-480 colon tumour cell line. BMC Cancer 3: 9
Ireson C, Jones DJL, Orr S, Coughtrie MWH,  Boocock D, Williams ML, Farmer PB, Steward WP, Gescher A (2002) Metabolism of cancer chemopreventive agent curcumin in human and rat intestine.  Cancer Epidemiol Biomarkers & Prev. 11: 97-104
       Lashley MR, Dicus CW, Brown K, Nantz MH (2003) Synthesis of a-hydroxytamoxifen and its 4-hydroxy analog. Org. Prep. Proced. Internat. 35: 231-238
Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG (2003) Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Brit. J. Cancer 44: 369
Manson MM (2003) Cancer prevention - The potential for diet to modulate molecular signalling. Trends Molec. Med. 9:11-18
Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, Smith LL, White INH (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63: 8461-8465
Morgan B, Thomas BL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin. Oncol. 21: 3955-3964
Perkins S, Clarke AR, Steward WP, Gescher AJ (2003) Age-related difference in susceptibility of ApcMin/+ mice towards the chemopreventive efficacy of dietary aspirin and curcumin. Brit. J. Cancer 88: 1480-1483
Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ (2002) Relationship between chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis.  Cancer Epidemiol Biomarkers & Prev. 11: 535-540.
Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparella KC, Lamb JH, Farmer PB, Stanley LA, Burke MD (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1.  Brit. J. Cancer 86: 774-778
Ratan HL, Gescher AJ, Steward WP, Mellon JK (2003) ErbB receptors: possible therapeutic targets in prostate cancer? BJU Internat. 92: 890-895
Smith LK, Botha JL, Benghiat A, Steward WP (2003) Latest trends in cancer incidence among UK South Asians in Leicester. Brit. J. Cancer 89: 70-73
   Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Seminars Oncol. 30: 32-38
 
  | The  GroupOncology in Leicester  | Why Chemoprevention  |  Mechanisms  Section
| Biomonitoring Section  |  Pharmacology Section  |  Achievements  | News |  References  |  Contacts